CEF1, Influenza Matrix Protein M1 (58-66) is an epitope derived from the matrix protein of the influenza A virus.
CAT No: R1275
CAS No:141368-69-6
Synonyms/Alias:141368-69-6;(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid;CEF1, Influenza Matrix Protein M1 (58-66);Matrix protein 1 (58-66);H-Gly-Ile-Leu-Gly-Phe-Val-Phe-Thr-Leu-OH; H-GILGFVFTL-OH;CHEMBL1869460;HY-P0137;NCGC00167248-01;FM110246;DB-230502;CS-0019779;Matrix protein m1(58-66)(influenza a virus);Matrix Protein M1 (58-66) (Influenza A virus) trifluoroacetate salt;Glycyl-l-isoleucyl-l-leucylglycyl-l-phenylalanyl-l-valyl-l-phenylalanyl-l-threonyl-l-leucine;944284-22-4;
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.